An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Copanlisib (Primary) ; Itraconazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 23 Jun 2017 Planned number of patients changed from 58 to 46.
- 28 Apr 2017 Planned primary completion date changed from 23 Mar 2018 to 28 Jun 2018.
- 24 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.